## NED 2020

Networking to Enhance Development

A Conference By and For Research Coordinators

Institute of Translation

iths.org/ned2020



## **Regulatory Year in Review**

THS

Institute of T

ACCELERATING

Slai) Arce les

## Karen Moe, Director UW Human Subjects Division



## Learning Objectives

UHS

Institute of

les



Identify key regulatory changes this past year



Explain how key regulatory changes affect certain types of research



Recognize how to apply those changes to your clinical research




Review the resources available for managing regulatory aspects of clinical research





#### **Regulatory changes**




Some changes make research easier, some add new requirements





## **The Common Rule**

# The human subjects regulations that 18 federal agencies have in common







## **The Common Rule**

#### How do you know if it applies to your research?

Look at your funding. It applies to human subjects research funded by virtually all federal agencies.





IHS

Institute of T

ACCELERATING





les





## **The Common Rule**

THS

Institute of 1

ACCELERATING

#### How do you know if it applies to your research?

Most academic and research IRBs routinely apply most of it to all studies, even if there is no federal funding





les





## **Revised Common Rule**

#### FIRST REVISION IN DECADES: TWO PARTS






## Why change the Common Rule?



Address evolving research methods & designs

Reduce regulatory burden for less risky studies

**Improve participant protections** 



Lengthy, repeated public consultation about need for changes





#### **Revised Common Rule**

#### Reduced regulatory work for less risky studies




- No IRB review required: Some public health research
- More research qualifies for exempt status, which means no further interaction with the IRB
  - Medical records reviews
  - Benign behavioural interactions
- No continuing review for low-risk research
- Consent or consent form waivers possible in more situations





#### **Revised Common Rule**

#### <u>New protection requirements</u>: Consent forms must quickly and clearly capture the study



- New specific elements: Secondary research; genetic analysis; return of results; commercial profit
- New required characteristics



#### New Required Characteristics of Consent



Key Information must be presented at the beginning

**Reasonable person standard** for what information is provided


Sufficient detail is provided

**Organized & presented** so as to facilitate understanding

**Opportunity for discussion** 







## **Key Information**

What does this mean?

**Key Information section** at the beginning of informed consent must begin with a <u>concise and focused</u> presentation of the <u>key information</u> that is most likely to assist a prospective subject or legally authorized representative in <u>understanding the reasons why</u> <u>one might or might not want to participate in the research</u>. This part of the informed consent must be organized and presented in a way that <u>facilitates comprehension</u>.





#### Important for participants, but...

These are "squishy" requirements

Federal agencies have provided very little guidance

Each IRB may have its own interpretation





#### Ē

## What should you do?





- Consent form template
- SOP Consent
- What information would they want?
- What information would influence their decision?

Look at resources from your IRB

Think about someone you know

Contact your IRB staff



 UW: <u>hsdinfo@uw.edu</u>, or contact the HSD team that works with your department

**C** Institute of Translational Health Scie



## What about the second part of the revision?

**JANUARY 21, 2020** 






## A <u>Single IRB</u> must do the review for all domestic institutions participating in any federally-funded study



## Supersedes and greatly expands the NIH Single IRB Policy

#### All federally-funded studies, not just NIH Collaborative AND classic multi-site studies





## Huge impact on multi-institutional research!

Institute of 1

ACCELERATING

#### See Breakout session 1B "Single IRB: The Promise and the Reality"

Human Subjects Division Single IRB website <a href="https://www.washington.edu/research/hsd/single-irb/">https://www.washington.edu/research/hsd/single-irb/</a>



les







## FDA: A quiet year



No regulatory changes
Many new draft or final guidance documents, but aimed at industry (not investigators or IRBs)

HS Institute of Translational Health Sciences

## In the works: Harmonization

#### **Common Rule**

45 CFR Part 46, Subpart A, common to 18 (soon 19) federal agencies and departments

#### FDA Human Subject Regulations

FDA Human Subject Regulations 21 CFR Parts 50 and 56 Clinical investigations involving FDAregulated products or supporting applications to FDA






National Institutes of Health New policy that affects **all** NIH-funded clinical research

New policy that affects a **very specific type** of NIH-funded research



## DRAFT Data Sharing and Management Policy A BIG CHANGE FROM THE OLD POLICY





- ► All NIH-funded research
- Mandatory sharing with colleague (including individuallevel data)
- Mandatory detailed data sharing plan, which must include steps to protect participant privacy

HS Institute of Translational Health Sciences accelerating research. IMPROVING HEALTH.




### What this means for Clinical Research Management ADDITIONAL RESPONSIBILITIES, PLANNING, AND RESOURCES



ITHS Institute of Translational Health Science Accelerating Research. IMPROVING HEALTH.

- Which data to share
- Storage and security
- Protection of participant privacy; what to tell them
- Request process, who handles it
- Data Use Agreements (content, who signs)
- Costs to put in the grant
- How to keep this going after the grant is over





A hot topic NIH is eager to move forward

Part of good stewardship & accountability initiatives

Clinical research managers should start thinking about how they would do this





#### Best source of information: NIH website

https://osp.od.nih.gov/scientific-sharing/nih-datamanagement-and-sharing-activities-related-to-publicaccess-and-open-science/





## Research involving the use of Human Fetal Tissue from elective abortions

- Tissue, cells, cell cultures, derivative products, xenografts, extra-embryonic cells and tissue (e.g., umbilical cord, cord blood)
- Some stem cell research

## New requirements for study team

NIH notice::


https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-128.html Human Subjects Division news announcement https://www.washington.edu/research/announcements/nih-humanfetal-tissue-research-clarifications-and-faqs-published/







## WASHINGTON STATE



Research conducted in Washington State or involving some stateowned records





#### Two helpful changes

**2019 Washington Legislative session** 



**Confidentiality Agreement no longer required** for state college & university records, including UW Medicine records. *All other laws still apply (e.g., HIPAA)* 



Extended family members and close friends can now be surrogate health care decision makers – includes research.





#### Where to find out more



#### Human Subjects Division GUIDANCE: Legally Authorized Representative

https://www.washington.edu/resea rch/policies/guidance-legallyauthorized-representative/







Research by the University of Washington



ITHS Institute of Translational Health Sciences Accelerating Research. IMPROVING HEALTH.

#### Which UW research?

Has primary goal of interactions with, or observations of, minors located anywhere (in-person or virtual)

#### **Does IRB status matter?**

No. This policy applies to all activities, even if the IRB says it is "not research" or is "exempt"

#### What are the requirements?

Registration; background checks and training for some personnel







### **UW Youth Programs Development & Support**

#### **Youth Policy Resource Website**

https://www.washington.edu/youth/policy/protecting-youth-at-uw-aps-10-13/

#### FAQ about research and the policy

https://www.washington.edu/youth/policy/protecting-youth-at-uw-aps-10-13/aps-10-13-info-for-researchers/

#### **Complete checklist of requirements**


https://s3-us-west-2.amazonaws.com/uw-s3-cdn/wpcontent/uploads/sites/129/2019/06/16200119/Policy-Quick-Reference-Checklist-9-2019-1.pdf







#### Summary of the 2019 regulatory changes







## General Resources Your IRB office staff Your IRB's website

#### **UW Human Subjects Division**

Email <u>hsdinfo@uw.edu</u> Website <u>https://www.washington.edu/research/hsd/</u> Monthly eNewsletter subscribe at <u>https://www.washington.edu/research/manage-your-office-of-research-</u> subscriptions/#hsd-newsletter





Networking to Enhance Development

## **Questions?**

ITHS

Institute of T

n<mark>slational Health Scien</mark> ARCH IMPROVING HEALTH

es

ITHS Institute of Translational Health Sciences Accelerating Research. IMPROVING HEALTH.



Networking to Enhance Development

## **Thank You**

ITHS

Institute of T

Slat ARCH IN es

ITHS Institute of Translational Health Sciences Accelerating Research. IMPROVING HEALTH.

## NED 2020

Networking to Enhance Development

A Conference By and For Research Coordinators

Institute of Translation

iths.org/ned2020